Ono Pharmaceutical Co., Ltd.

Panasonic Corporation

Takeshi Matsushita

Takuya Nishio

Tetsuya Sekiguchi

Akiharu Ishida

Tatsuya Komagata

Kazuyuki Ohmoto

Masashi Kato

Seishi Katsumata

Junichiro Manako

Yasuyuki Okabe

Hiroto Mizouchi

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes

The present invention provides a somatostatin receptor subtype 2 agonist. A disclosed compound represented by the general formula (I): wherein all symbols have the same definitions as described in the specification;a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing is a low-molecular compound having strong somatostatin receptor subtype 2 agonistic activity, and thus can be administered in a simple manner, has high stability and has low toxicity. Therefore, the present compound is useful for prophylaxis and/or therapy of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.

Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): [wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

The present invention relates to the compound represented by formula (I)A-X&#x2014;Y&#x2014;Z&#x2014;B&#x2003;&#x2003;(I)(wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.

Tricyclic heterocycle compound

A recording and reproducing device () in which, when the power is turned off, the state of the power can be controlled to be in either one of a first power-off state and a second power-off state in which the recording and reproduction device () can be started faster than in the first power-off state. The recording and reproducing device () has a 'first standby mode' during which the power state of the device is controlled to the first power-off state when the device receives a power-off instruction, and a 'second standby mode' during which the power state of the device is controlled to the second power-off state when the device receives a power-off instruction. A power controller () makes, according to a setting time zone, the second standby mode active only for a predetermined time zone including the setting time zone.

Growing community of inventors

Osaka, Japan

Takeshi Matsushita